minimally-invasive-surgery
(7)
Tamir Wolf
Tamir Wolf is the CEO and co-founder of Theator, a Palo Alto and Tel Aviv based company building a surgical intelligence platform that uses AI and computer vision to analyze surgical video and reduce variability in the operating room. A physician turned entrepreneur, he earned an MD and PhD from the Technion, served as a medical officer in an elite Israeli Navy unit, and founded two earlier medical device companies before starting Theator in 2018. His stated goal is to codify surgery so that where a patient lives no longer dictates the quality of care they receive.
Mark Foster
Mark Foster is the president and CEO of CurvaFix, a Bellevue, Washington medical device company building curved intramedullary implants that follow the natural bend of the pelvis to repair fractures. He took the top job in July 2023, the same week the company closed a $39 million Series C led by MVM Partners, and his mandate is commercial scale: turning a novel, FDA-cleared implant into a nationally distributed product. Before CurvaFix he ran Trice Medical and led the U.S. sports medicine business at Smith & Nephew, part of roughly 24 years spent almost entirely inside orthopedics and medical devices.
Yunfei Cao
Yunfei 'Richard' Cao is the co-founder and CEO of Angio8 (通甪科技), a Shenzhen-based startup building a next-generation surgical robot for minimally invasive vascular interventional surgery. A Stony Brook biomedical engineer who cut his teeth inside the Boston medical-device machine at Vention Medical, SunMed and China Med Device, Cao now runs a cross-Pacific company - engineering brains in Boston, manufacturing and clinical work in Shenzhen - aimed at letting doctors steer catheters and guidewires by robot instead of by hand.
Robert Masson
Robert Masson is a neurosurgeon turned founder who runs eXeX (Expanded Existence), an AI and mixed-reality platform that captures surgical mastery and pipes holographic guidance into the sterile field. With more than three decades of spine surgery and 13,000-plus procedures behind him, he made global headlines for bringing the Apple Vision Pro into the operating room as a touch-free logistics tool. He is also the founder of the Masson Spine Institute and, at 52, raced to a podium at the Rolex 24 at Daytona alongside his eldest son.
Peter Martin
Peter Martin is the co-founder, President and CEO of Siesta Medical, a Los Gatos medical device company building minimally invasive treatments for obstructive sleep apnea that need no masks and no machines. Since 2009 he has guided the company from an idea to FDA-cleared products - the Encore System, the Revolution Suture Passer and the AIRLIFT hyoid suspension procedure - that reposition the airway with two small implants and a stitch. A Duke and Stanford trained mechanical engineer, he spent 15-plus years in medical device operations before turning Siesta into one of the most-cited names in surgical sleep apnea care.
Rui Jing
Rui Jing Jiang is the Founder and CEO of Avisi Technologies, a Redwood City-based clinical-stage medical device company developing VisiPlate, the world's thinnest freestanding ophthalmic implant for treating glaucoma. Built on University of Pennsylvania nanotechnology, VisiPlate is a multichannel aqueous shunt composed of alumina and Parylene-C that is 20 times thinner than a human hair. Rui Jing co-founded the company in 2017 as a junior at Penn's Wharton School, won the $100,000 President's Innovation Prize in 2018, secured FDA Investigational Device Exemption approval in October 2025 for the US SAPPHIRE trial, and closed a $10.7M Series A in February 2026 to advance pivotal clinical development.
Robert Chang
Robert Chang is the President and CEO of Myra Vision, a Campbell, California medtech company developing the Calibreye Titratable Glaucoma Therapy (TGT) Surgical System - an adjustable aqueous shunt designed to give glaucoma surgeons real-time, non-invasive control over intraocular pressure. With over 30 years of medical device executive experience spanning co-founding Ample Medical, leading MVRx, and serving as CTO at Sadra Medical (acquired by Boston Scientific), Chang brings a rare combination of hands-on engineering depth and serial CEO-level leadership to one of ophthalmology's most intractable surgical challenges. Myra Vision has raised $50M+ across seed, Series A, and a $25M Series B in 2023, and in early 2026 enrolled its first patient in the FDA-approved ADAPT pivotal study.